Trial Profile
A Phase 1, Open-label, Single-dose Study of the Pharmacokinetics, Safety, and Tolerability of SSP-004184 (SPD602) in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferitazole (Primary)
- Indications Iron overload
- Focus Pharmacokinetics
- Sponsors Shire
- 19 May 2014 New trial record